Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
The Big Pharma is paying $30 million upfront to pick up the rights to the program and take it into the clinic.
Newly minted CEO Vas Narasimhan is paying a hefty premium to establish Novartis as a frontrunner in the emerging gene therapy sector.
After a tough few months, sources are telling the Financial Times that Celgene is looking to buy out some biotech names with ties to the company.
The $400 million deal gives Novo worldwide rights to an epigenetic treatment of the disease that is closing in on the start of a phase 2 trial.
Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.
Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.
Six months after getting off its series A, Kymera Therapeutics has nabbed a deal with GlaxoSmithKline, although exact details are under wraps.
Roche snapped up a remyelinating drug candidate for multiple sclerosis from an alliance with Versant that also spawned startup Pipeline Therapeutics.
The Terns deal is a poster child of "Lilly China Innovation and Partnerships," a new model in place of Lilly's Shanghai R&D center shuttered…
After selling Kite for $11.9 billion, former executives Arie Belldegrun and David Chang are working on off-the-shelf CAR-T.